ALT: a man is smiling and saying it 's madness

We found lower risks of adverse CV and kidney outcomes and mortality with GLP-1RA use compared with DPP4i use among patients with lupus and T2D.

Written by Elba MedinaReviewed by Brian Rifkin;Sophia AmbrusoToday, current methods for measuring kidney function, due to several critical limitations, need to be reimagined. In the reimagining Kidney...

Explore how we are uncoupling hemostasis and thrombosis via Factor XI inhibitors and how it is may change anticoagulation for atrial fibrillation in kidney disease

Tirzepatide reduced weight, A1c, and insulin dose in type 1 diabetes in a small randomized controlled trial.

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

By. Husam Alzayer, MD, MSc, MRCPIReviewed by Sophia Ambruso, DOIntroduction Bleeding and thrombosis represent one of the many paradoxes faced by patients with kidney disease. As kidney function declin...

A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD

the use of spironolactone in patients on dialysis did not alter mortality or hospitalizations for heart failure. Similar results were seen in the simultaneously released ALCHEMY trial.

Written by: Henny Adriani PuspitasariIntroduction:IgA nephropathy (IgAN) and IgA vasculitis nephritis (IgAVN) are kidney diseases that can significantly impact children's health. While they share some...

KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025 Selection Committee Member: Swee-Ling Levea @SweeLevea Swee-Ling Levea is an Associate Professor of Medicine at Unive…

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR-Reduced (Empagliflozin Outcome ...

Author: Brian Rifkin, MDHattiesburg ClinicHattiesburg, MSCare of patients with diabetes has advanced significantly since Banting and Best discovered insulin over a century ago. The prognosis of type 1...

This pooled cross-sectional study explores prescribing rates for glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among US patients with type 1 diabetes.

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythm...